Stockreport

Edesa Biotech Reports Statistically Significant Mortality Reductions in Phase 2 ARDS Drug Study

Edesa Biotech, Inc. - Common Shares  (EDSA) 
PDF Mortality reduction in critically ill subjects at 28 days revised favorably, statistically significantEB05 demonstrated an 84% reduction in the risk of dying when compar [Read more]